Histopathology reporting for personalised medicine: focus on clinical utility

被引:0
|
作者
Mason, Anna Elizabeth [1 ]
Varma, Murali [1 ]
机构
[1] Univ Hosp Wales, Dept Cellular Pathol, Cardiff, Wales
关键词
diagnosis; neoplasms; pathology; surgical; process assessment; health care; medical oncology;
D O I
10.1136/jclinpath-2022-208185
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Histopathology guidelines generally focus on standardised collection of data items to facilitate completeness and reproducibility of histopathology reporting. A data item is categorised as either core (mandatory) or non-core (recommended but not mandatory), irrespective of the clinical scenario. However, a data item that is critical for patient management in one clinical setting may have little clinical significance in another setting. A diagnosis of limited extent Gleason score 3+3=6 prostate cancer is critical in a patient being investigated for raised serum prostate-specific antigen but would be clinically irrelevant in a repeat biopsy from a patient on an active surveillance protocol. We outline an alternative approach that is focused on the clinical utility of the data items and the requirements of personalised medicine. While all core data items are required to be reported, understanding how these parameters are used to guide patient management will enable pathologists to focus time and resources on the critical aspects of an individual case. Detailed immunohistochemical workup and obtaining a second opinion would not be necessary if resolution of the differential diagnosis is of limited clinical significance. We also highlight some challenges encountered when adopting this approach and suggest some solutions that could positively impact histopathology reporting and patient care.
引用
收藏
页码:525 / 528
页数:4
相关论文
共 50 条
  • [31] A boost for personalised medicine
    不详
    LANCET HAEMATOLOGY, 2015, 2 (03): : E82 - E82
  • [32] Bioethics and personalised medicine
    Kochanski, A.
    FEBS OPEN BIO, 2019, 9 : 8 - 8
  • [33] Pharmacogenetics and personalised medicine
    Kalow, W
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2002, 16 (05) : 337 - 342
  • [34] The ultimate personalised medicine
    Currow, D. C.
    Abernethy, A. P.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2012, 66 (09) : 824 - 826
  • [35] Personalised Transfusion Medicine
    D'Alessandro, Angelo
    Liumbruno, Giancarlo
    BLOOD TRANSFUSION, 2019, 17 (04) : 255 - 257
  • [37] Personalised medicine for hypertension
    Brown, Morris J.
    BMJ-BRITISH MEDICAL JOURNAL, 2011, 343
  • [38] Nuclear medicine in the era of personalised medicine
    Lee, Sze Ting
    Scott, Andrew M.
    INTERNAL MEDICINE JOURNAL, 2018, 48 (05) : 497 - +
  • [39] Confidential reporting: from aviation to clinical medicine
    Nicholson, AN
    Tait, PC
    CLINICAL MEDICINE, 2002, 2 (03) : 234 - 236
  • [40] Maximizing the clinical utility of descriptive lymphoid pathology reporting
    McCalmont, Timothy H.
    SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2018, 37 (01) : 75 - 80